CMS tracks the use of a variety of psychoactive drugs including antipsychotics, hypnotics, anti-depressants, and anti-anxiety medications.
Antipsychotics are a group of drugs used to manage psychosis including delusions and hallucinations. An antipsychotic drug is a chemical substance that crosses the blood–brain barrier and acts primarily upon the central nervous system where it affects brain function, resulting in changes in perception, mood, consciousness, cognition, and behavior.
Atypical antipsychotic medications also called “novel” antipsychotics have different chemical characteristics from the older, conventional drugs used to treat psychosis. Atypical or novel medications are far less likely to side effects. In addition, atypical antipsychotics may be effective in some cases where there is a resistance to older drugs.
Drugs in this group contain Clozapine ( Clozaril), Risperidone (Risperdal), Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Abilify), Paliperidone (Invega), Iloperidone (Fanapt), Asenapine (Saphris), and Lurasidone (Latuda).
Traditional antipsychotics include Haloperidol (Haldol), Chlorpromazine (Thorazine), Fluphenazine (Prolixin), Thiothixene (Navane) and others.
Black box warning: The Food and Drug Administration has issued a warning for all antipsychotic medications after studies revealed an increased risk of serious cardiovascular and cerebrovascular events including an increased risk of death.
CMS regulates the use of medication. According to its State Operations Manual:
Proper medical selection in prescribing (including dose, duration, and type of medication(s) may help stabilize or improve a resident’s outcome, quality of life and functional capacity. Any medication or combination of medication – or the use of a medication without adequate indications, in excessive dose, for an excessive duration, or without adequate monitoring – may increase the risk of a broad range of adverse consequences such as medication interactions, depression, confusion, immobility, falls, and related hip fractures.
Title 22 of the California code of regulations Section 72528(c) states:
Before initiating the administration of psychotherapeutic drugs… facility staff shall verify that the patient’s health record contains documentation that the patient has given informed consent to the proposed treatment or procedure.
Informed consent requires the attending physicians to explain the elements of the residents’ care plan, including the use of medications, and obtain consent from the resident or a designated family member before any treatment is administered.
Family member who is available and willing to make health care decisions, and
Conservator of the person, and
Other person with legal authority to make health care decisions on his or her behalf.
There are a number of skilled nursing facilities in California with special treatment programs (STPs).
These facilities provide 24 hour care to residents with a primary psychiatric diagnosis who may also possess a co-existing medical conditions or to residents with 24 hour medical needs who have secondary behavioral conditions.
These facilities are generally locked units, licensed by the California Department of Public Health and certified by the California Department of Mental Health. Physicians and psychiatrists often appropriately prescribe antipsychotic medication to patients with diagnosed mental disorders including delusions, hallucinations and schizophrenia. Special treatment programs also provide individualized plans of care, including behavior modification and special activities to help residents maintain quality of life and the highest level of functioning.
The federal government keeps track of the number of residents receiving anti-psychotic medication and posts updates on CMS Compare. However, this information is not risk-adjusted to include all the major psychiatric illnesses in which these medications are commonly indicated and helpful such as bi-polar disorder, depression with psychotic features, and schizo-affective disorder.
In other words, the newest version of Nursing Home Compare only excludes residents with Schizophrenia, Tourette’s syndrome, and Huntington’s disease and does not exclude residents with other psychiatric disorders. As a result, STPs often report a higher number of residents on antipsychotic medication because many residents suffer from psychiatric conditions, where antipsychotic medication is appropriate.
